Skip to content
Bomb Report – Lifestyle
Author:
Vicore Pharma Holding
Vicore Pharma Announces Third Quarter 2026 Financial Results and Provides Business Update
November 5, 2026
Vicore Announces the Nomination Committee for the 2027 Annual General Meeting
November 3, 2026
Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference
November 2, 2026
Vicore’s Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results
October 22, 2026
Increase in Number of Shares and Votes in Vicore Pharma
September 30, 2026
Vicore Pharma to Present in The Stifel 2026 Virtual Immunology and Inflammation Forum
September 17, 2026
Vicore Pharma to Participate in Upcoming Healthcare Conferences
September 1, 2026
Vicore Pharma to Present at the European Respiratory Society Congress 2026
August 24, 2026
Vicore Pharma to Participate in the Leerink Therapeutics Forum
July 7, 2026
Vicore Pharma Appoints Rob Slack as Chief Scientific Officer
July 6, 2026
1
2
Next Page
→